Risk factors for 6-month continuation of S-1 adjuvant chemotherapy for resected pancreatic cancer.
Aoyama T, Katayama Y, Murakawa M, Asari M, Kanazawa A, Higuchi A, Shiozawa M, Kobayashi S, Ueno M, Morimoto M, Ohkawa S, Akaike M, Yamamoto N, Yoshikawa T, Rino Y, Masuda M, Morinaga S.
Aoyama T, et al. Among authors: kobayashi s.
Cancer Chemother Pharmacol. 2014 Dec;74(6):1235-40. doi: 10.1007/s00280-014-2601-y. Epub 2014 Oct 9.
Cancer Chemother Pharmacol. 2014.
PMID: 25297990